Evidence map›Paper›PMID 37552238›Full record

ReviewDiabetologia2023

Incretins beyond type 2 diabetes.

Chantal Mathieu, Iraj Ahmadzai

Open access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Diabetologia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. EndoBridge 2024: pearls and highlights.Hormones (Athens, Greece) · 2025
    Article
  3. Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Chantal MathieuDepartment of Endocrinology, UZ Gasthuisberg, KU Leuven, Leuven, Belgium. chantal.mathieu@uzleuven.be.ORCID http://orcid.org/0000-0002-4055-5233
Iraj AhmadzaiDepartment of Endocrinology, UZ Gasthuisberg, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0001-9980-6925
Universitair Ziekenhuis Leuven · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Incretin-based therapies, in particular glucagon-like peptide-1 (GLP-1) receptor agonists, have been evaluated in other forms of diabetes, but randomised controlled trials are mainly limited to people living with type 1 diabetes. In this review we present the evidence issuing from these trials and discuss their clinical implications as well as the difficulties in interpreting the data. In type 1 diabetes, the addition of GLP-1 receptor agonists to intensive insulin therapy lowers weight and required insulin doses compared with placebo, but the effects on glucose control (HbA

Indexed as

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHumansHypoglycemic AgentsIncretinsInsulinGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsIncretinsInsulinGLP-1 receptor agonistsGlucose controlIncretinsMonogenic diabetesReviewType 1 diabetesWeight

Identifiers

PMID37552238
OpenAlexW4385660133

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.